Applications

1771 – Axicabtagene ciloleucel therapy for patients with relapsed or refractory follicular lymphoma

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation Not applicable
  • Pre-MSAC consultation Closed
  • Outcome Not supported

Application details

Reason for application

Highly Specialised Therapy – National Health Reform Agreement.

Service or technology in this application

Axicabtagene ciloleucel is a CAR T-cell therapy that is produced using a patient’s own T-cells. A patient’s T-cells are collected and genetically modified in a lab to express an anti-CD19 chimeric antigen receptor that targets the lymphoma B-cells. The modified T-cells are multiplied and then infused back into the patient where they target and kill the cancerous lymphoma B-cells.

Axicabtagene ciloleucel is used when patients with follicular lymphoma do not respond to (refractory), or relapse (come back) after, other types of treatment, such as chemotherapy.

Type: Investigative technology

Medical condition this application addresses

Follicular Lymphoma (FL) is a type of blood cancer that changes certain blood cells in your body called B-cell lymphocytes. It can affect lymph nodes and the lymphatic system. Follicular lymphoma is considered an indolent lymphoma, which means it is usually slow growing.

Consultation survey and deadlines

  • PASC consultation: Expedited – bypassing PASC
  • MSAC consultation: Closed Friday 14 June 2024

Meetings to consider this application

  • PASC meeting: Bypassing PASC
  • ESC meeting: 13–14 June 2024
  • MSAC meeting: 1–2 August 2024